Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IV study of tailored therapy with peg interferon alfa 2b and ribavirin for patients with genotype 3 and high viral load. Genotype 3 extended treatment for HCV (GET-C study).

Next Previous
X
Search
Trial Profile

Phase IV study of tailored therapy with peg interferon alfa 2b and ribavirin for patients with genotype 3 and high viral load. Genotype 3 extended treatment for HCV (GET-C study).

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 06 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Peginterferon alfa-2b/ribavirin (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms GET-C
  • Sponsors Merck Sharp & Dohme

    • Most Recent Events

    • 28 Jul 2009 Actual patient number (146) added as reported by ClinicalTrials.gov.
    • 21 Mar 2008 Status change from suspended to discontinued, as reported by clinicaltrials.gov.
    • 17 Jan 2008 The expected completion date for this trial is now 1 Aug 2008 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top